Agilent Technologies Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy. This approval is based on the evaluation of PD-L1 expression in the KEYNOTE-B96 clinical trial and marks the seventh FDA-approved companion diagnostic indication for this assay in use with KEYTRUDA. The test is also indicated in the U.S. for use in other cancers, including non-small cell lung cancer, esophageal squamous cell carcinoma, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and gastric or gastroesophageal junction adenocarcinoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210235592) on February 11, 2026, and is solely responsible for the information contained therein.